Altheia lands $11M series A

Altheia Science S.r.l. (Milan, Italy) closed an $11 million series A round. The round could be expanded by another $6.7 million with the participation of institutional investors, the company said.

Paolo Rizzardi, Altheia's chairman and CEO, told BioCentury the company has two lead PD-L1-based cell therapy programs in preclinical development to treat Type I diabetes and multiple sclerosis. The company hopes to reach the clinic with one of the two in 2021. ...